Targeting the Tumor Microenvironment with Lipid-Based Immunotherapies episode artwork

EPISODE · Apr 17, 2024 · 35 MIN

Targeting the Tumor Microenvironment with Lipid-Based Immunotherapies

from The Bio Report · host Levine Media Group

Lipids have long been used as drug delivery vehicles, but HighField Biopharmaceutics is repurposing lipids as drugs to fight cancer. The company’s technology platform is seeking to change the immunotherapy landscape with new treatments that are better targeted, more potent, and less toxic. We spoke to Don Wyatt, chief business officer for HighField Biopharmaceuticals, about the tumor microenvironment, HighField’s platform technology, and how it is developing lipid-based medicines to overcome challenges of existing immunotherapies.

Don Wyatt, chief business officer for Highfield Biopharmaceuticals, discusses the tumor microenvironment, HighField’s platform technology, and how it is developing lipid-based medicines to overcome challenges of existing immunotherapies.

NOW PLAYING

Targeting the Tumor Microenvironment with Lipid-Based Immunotherapies

0:00 35:04

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of The Bio Report?

This episode is 35 minutes long.

When was this The Bio Report episode published?

This episode was published on April 17, 2024.

What is this episode about?

Lipids have long been used as drug delivery vehicles, but HighField Biopharmaceutics is repurposing lipids as drugs to fight cancer. The company’s technology platform is seeking to change the immunotherapy landscape with new treatments that are...

Can I download this The Bio Report episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!